Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ether doai
Patent
1997-05-09
1999-02-09
Geist, Gary
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ether doai
514826, 436 71, 568671, 568687, A61K 3108
Patent
active
058695370
ABSTRACT:
This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.
REFERENCES:
"Secretory Products of Macrophages" by Carl F. Nathan, J. Clin. Invest. vol. 79, Feb. 1987, pp. 319-326.
"Adhesion receptors of the Immune System" by Timothy A. Springer, Nature vol. 346, Aug. 1990, pp. 425-433.
"Biochemistry of Phagocyte Chemotaxis" by Elliott Schiffmann and John I. Gallin, Current Topics in Cellular Regulation, vol. 15, pp. 203-261.
"Platelet-derived Growth Factor and Transforming Growth Factor-B Enhance Tissue Repair Activities by Unique Mechansims" by Glenn F. Pierce, Thomas A. Mustoe, Jane Lingelbach, Victoria R. Masakowski, Gail L. Griffin, Robert M. Senior and Thomas F. Deuel, The Journal of Cell Biology, vol. 109, Jul. 1989, pp. 429-440.
"Cloning and Sequencing of the cDNA for Human Monocyte Chemotactic and Activating Factor (MCAF)" by Yasuji Furutani, Hideki Monura, Mitsue Notake, Yoshihiro Oyamada, Toshikazu Fukui, Masaaki Yamada, Christian G. Larsen, Joost J. Oppenheim, and Kouji Matsushima, Biochemical and Biophysical Research Communications, vol. 159, No. 1, Feb. 1989, pp. 249-255.
"The Pathogenesis of Atherosclerosis--An Update" by Russell Ross, Ph.D., The New England Journal of Medicine, vol. 314, No. 8, Feb. 1986, pp. 488-500.
Editorial Review: "Focal and Segmental Glomerulosclerosis: Analogies to Atherosclerosis", Kidney International, vol. 33 (1988) pp. 917-924.
"Studies of Leukotriene B.sub.4 -Specific Binding and Function in Rat Polymorphonuclear Leukoscytes: Absence of a Chemotactic Response" by Regina A. Kreisle, Charles W. Parker, Gail L. Griffin, Robert M. Senior and William F. Stetson, The Journal of Immunology, vol. 134, No. 5, May 1985, pp. 3356-3363.
Novel effects of 1-0-Hexadecyl-2-Acyl-Sn-Glycero-3-Phosphorylcholine Mediators on Human Leukocyte Function: Delineation of the Specific Roles of the Acyl Substituents by Edward J. Goetzl, Claudia K. Derain, Alfred I. Tauber and Frank H. Valone, Biochemical and Biophysical Research Communicatons, vol. 94, No. 3, Jun. 1980, pp. 881-888.
"Mechanisms Underlying the Anti-Inflammatory Effects of Essential Fatty Acid Deficiency in Experimental Glomerulonephritis" by Brad H. Rovin, James B. Lefkowith and George F. Schreiner, The Journal of Immunology, vol. 145, No. 4, Aug. 1990, pp. 1238-1245.
"Lysophosphatidylcholine: A Chemotactic Factor for Human Monocytes and its Potential Role in Atherogenesis" by Mark T. Quinn, Sampath Parthasarathy and Daniel Steinberg, Proc. Nat'l. Acad. Sci. U.S.A., vol. 85, Apr. 1988, pp. 2805-2809.
"A Monoculear Cell Component in Experiental Immunological Glomerulonephritis" by George F. Schreiner, Ramzi S. Cotran, Victoriano Pardo and Emil R. Unanue, The Journal of Experimental Medicine, vol. 147, (1978) pp. 369-384.
"Modulation of la and Leukocyte Common Antigen Expression of Rat Glomeruli During the Course of Glomerulonephritis and Aminonucleoside Nephrosis" by George F. Schreiner, Ramzi S. Cotran and Emil R. Unanue, Laboratory Investigation, vol. 51, No. 5, (1984) pp. 524-533.
"Prevention of Clumerulonephritis and Prolonged Survival in New Zealand Black/New Zealand White F.sub.1 Hybrid Mice Fed as Essential Fatty Acid-deficient Diet", by Eric F. Hurd, John M. Johnston, Janice R. Okita, Paul C. MacDonald, Morris Ziff and James N. Gilliam, J. Clin. Invest., vol. 67, Feb. 1981, pp. 476-485.
"Essential Fatty Acids Deficiency Depletes Rat Clomeruli of Resident Macrophages and Inhibits Angiotensin II-Induced Eicosanoid Synthesis", by James B. Lefkowith and George Schreiner, J. Clin. Invest., vol. 80, Oct. 1987, pp. 947-956.
"Essential Fatty Acid Depletion of Renal Allografts and Prevention of Rejection" by George Schreiner, Wayne Flye, Elizabeth Brunt, Ken Korber, and James B. Lefkowith, Science, vol. 240, May 1988, pp. 1032-1033.
"The Antiinflammatory Effects of Essential Fatty Acid Deficiency in Experimental Glomerulonephritis" by George F. Schreiner, Brad Rovin and James F. Lefkowith, The Journal of Immunology, vol. 143, No. 10, Nov. 1989, pp. 3192-3199.
"Essential Fatty Deficiency During Acute Puromycin Nephrosis Ameliorates Late Renal Injury" by Jonathan R. Diamond, Ivona Pesek, Salvatore Ruggieri and Morris J. Karnovsky, The American Physiological Society, pp. F798-F807.
"Essential Fatty Acid Deficiency Ameliorates Acute Renal Dysfuction in the Rat After the Administration of the Aminonucleoside of Puromycin" by K.P.G. Harris, J.B. Lefkowith, S. Klair and G.F. Schreiner, J. Clin. Invest., vol. 86, Oct. 1990, pp. 1115-1123.
"Essential Fatty Acid Deficiency Prevents Multiple Low-Dose Streptozotocin-Induced Diabetes in CD-1 Mice", by James R. Wright, Jr., James B. Lefkowith, George Schreiner and Paul E. Lacy, Proc. Nat'l Acad. Sci., U.S.A., vol. 85, Aug. 1988, pp. 6137-6141.
"Macrophage-Specific Chemotacitc Lipid Release by in Vivo Streptozocin-Administered Mouse Islets" by Andrew Muir, Brad H. Rovin, Paul E. Lacy, and George Schreiner, Diabetes, vol. 40, Nov. 1991, pp. 1459-1466.
"The Ratio of Trienoic: Tetraenoic Acids in Tissue Lipids as a Measure of Essential Fatty Acid Requirement" by Ralph T. Holman, J. Nutrition, 70 (1960) pp. 405-410.
"Reduced Exudation and Increased Tissue Proliferaton During Chronic Inflammation in Rats Deprived of Endogenous Prostagland in Precursors", by I.L. Bonta, M.J. Parnham and M.J.P. Adolfs, Prostaglandins, vol. 14, No. 2 , Aug. 1977, pp. 295-307.
"Chemotaxis and Methylation in a Macrophage Cell Line" by Robert R. Aksamit, and Peter S. Backlund, Jr., Surv. Immunol. Res.vol. 2, (1983) pp. 150-154.
"A 48-Well Micro Chemotaxis Assembly for Rapid and Accurate Measurement of Leukocyte Migration" by Werner Falk, Richard H. Goodwin, Jr., and Edward J. Leonard, Journal of Immunological Methods, vol. 33 (1980), pp. 239-247.
"Raspailynes, Novel Long-Chain Acetylenic Enol Ethers of Glycerol from the Marine Sponges Raspailia pumila and Raspailia ramosa" by G. Guella et al. Heveltica Chimica Acta. 70: 1050-1062 (1987).
Chem. abstr., Bacon et al., 114:99349., 1991.
Lange, III Louis G.
Schreiner George F.
Carr Deborah D
CV Therapeutics
Geist Gary
LandOfFree
Macrophage lipid chemoattractant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrophage lipid chemoattractant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrophage lipid chemoattractant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1948814